Trials / Unknown
UnknownNCT02430896
Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to identification of neuropsychological, genetic and neuroimaging markers and treatment response predictors of attention-deficit/hyperactivity disorder (ADHD). Participants who take the standardized pharmacotherapy (methylphenidate or atomoxetine) for ADHD will be observed for 52 weeks. They will do several neuropsychological, neuroimaging and genetic tests at visit 1\~6.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylphenidate (MPH) | Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks. |
| DRUG | Atomoxetine | Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks. |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2020-06-30
- Completion
- 2020-12-31
- First posted
- 2015-04-30
- Last updated
- 2019-07-05
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02430896. Inclusion in this directory is not an endorsement.